PDF(Pubmed)
Abstract：
This study explored the impact of short-term coronavirus disease 2019 (COVID-19) restrictions on the efficacy of atropine 0.01% eyedrops on myopia control in a multiethnic cohort of Australian children. In the Western Australia Atropine for the Treatment of Myopia study, 104 and 49 children were randomized to receive atropine 0.01% eyedrops and a placebo, respectively. We compared the 1-year myopia progression and axial elongation following the 2-month lockdown in 2020 to the same months in 2019 and 2021, i.e., the 1-year myopia progression up to May 2019-October 2019 (non-COVID-19) versus the 1-year progression up to May 2020-October 2020 (COVID-19 period), and the 1-year progression up to May 2021-October 2021 (non-COVID-19) versus the 1-year progression up to the same months in 2020. After excluding participants who withdrew, completed their treatment phase prior May 2020, or those whose study visits did not fall between May 2020 and October 2020, 65 participants (mean age at baseline = 11.8 ± 2.5 years) were included in the final analysis (49 in the treatment group; 16 in the placebo group). After correcting for age, sex, and ethnicity, there was no significant main effect of the short-term lockdown on the rate of spherical equivalent or axial length change. However, there was a lockdown × treatment interaction effect on the rate of axial elongation (P = 0.007). This was such that in the treatment group, the 1-year axial elongation was faster during lockdown by 0.056 mm compared to the nonlockdown periods (P = 0.009), while the rate of axial elongation in those on the placebo eye drops was similar during lockdown and nonlockdown. Our findings suggest that there is a decreased efficacy of low-concentration atropine even with relatively lenient restrictions lasting for a few months.
摘要：
这项研究探讨了短期冠状病毒病2019（COVID-19）限制对澳大利亚多种族儿童队列中0.01％阿托品滴眼液对近视控制疗效的影响。在西澳大利亚阿托品治疗近视的研究，104和49名儿童随机接受阿托品0.01%滴眼液和安慰剂，分别。我们将2020年锁定2个月后的1年近视进展和轴向伸长与2019年和2021年的同一个月进行了比较，即截至2019年5月至2019年10月的1年近视进展（非COVID-19）与截至2020年5月至2020年10月的1年近视进展（COVID-19期间），以及截至2021年5月至2021年10月的1年进展（非COVID-19）与截至2020年同一月的1年进展。在排除退出的参与者之后，在2020年5月之前完成治疗阶段,或在2020年5月至2020年10月期间未完成研究访视的患者,有65名参与者(基线时平均年龄=11.8±2.5岁)被纳入最终分析(治疗组49名;安慰剂组16名).校正年龄后,性别,和种族,短期锁定对球形当量或轴向长度变化率没有显着主要影响。然而,轴向伸长率存在锁定×治疗交互作用(P=0.007)。在治疗组中，1年轴向伸长在锁定期间比非锁定期间快0.056mm（P=0.009），而安慰剂滴眼液的轴向伸长率在锁定和非锁定期间相似。我们的发现表明，即使相对宽松的限制持续几个月，低浓度阿托品的疗效也会降低。
